For early prostate cancer, 'active surveillance' is now the number 1 choice
Repercussão envolvendo San Francisco chama atenção em Fitness.
Notícias
Acompanhe as Notícias da Recifes
Fique por dentro das últimas novidades sobre tecnologia, negócios e empreendedorismo.
Half of prostate cancer focal therapy use found to fall outside current guideline-supported groups
Repercussão envolvendo fonte internacional chama atenção em Fitness.
Researchers develop mathematical measures to better personalize therapy for prostate cance
Researchers at Moffitt Cancer Center have developed three mathematical biomarkers that may help physicians personalize adaptive therapy for prostate cancer by predicting treatment outcomes early in treatment. The biomarkers are specialized mathematical measures calculated from ro
Ultra-processed foods linked to notably higher prostate cancer risks
Ultra-processed foods (UPFs) account for nearly 60% of adults' and 70% of children's energy intake in the United States. Destaque: 60%, 70%.
Traditional prostate cancer risk factors do not predict hormone therapy benefit, study fin
A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the semina
How a Veterans Affairs study can help guide prostate cancer treatment
A nationwide Veterans Affairs (VA) study comparing two leading treatments for metastatic prostate cancer may help doctors choose the right drug for each patient, said a Rutgers Cancer Institute physician-scientist whose invited editorial accompanies the research.
Prostate cancer prognosis linked to prostate-specific antigen levels below threshold
After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that treatment is working. A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is an indicator of improved patient survival. The
Radiopharmaceutical may benefit patients with metastatic prostate cancer sooner
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a Phase III clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and inves